Results

Total Results: 1,455 records

Showing results for "analyze".

61. Interventions for Preventing Cognitive Decline, Mild Cognitive Impairment, and Alzheimer’s Disease | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/cognitive-decline/research-protocol
    December 01, 2020 - We will therefore group studies in the most appropriate way possible and analyze data for specific subgroups … When sufficient trial data are not available, we will analyze high quality observational studies of interventions … As noted above, we will separately analyze studies by the average age of the subjects enrolled and study … If certain comparisons can be pooled, we will meta-analyze the data using a random effects model.

62. Nonpharmacologic Interventions for Agitation and Aggression in Dementia | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/dementia-agitation-aggression/research
    December 01, 2019 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

63. Medical Therapies for Locally Advanced Gastric Adenocarcinoma (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/gastric-cancers-protocol.pdf
    January 01, 2024 - To reduce clinical heterogeneity, we will analyze studies of patients with resectable tumors or who … For other subgroups which may be effect modifiers such as biomarkers and functional status, we will analyze … We will analyze RCTs and NRSIs separately unless there is reason to believe the studies are sufficiently

64. Cer-235-Pharma-Nonpharm-Ptsd-Update-Appendix-G-1 (xls file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-235-pharma-nonpharm-ptsd-update-appendix-g-1.xlsx
    November 12, 2020 - G-1. Additions to ROB Template Table G-2. Additions to risk of bias template Rater Author, Year Selection Bias Domain: Randomization Adequate? Selection Bias Domain: Allocation Concealment Adequate? Selection Bias Domain: Groups Similar at Baseline? Selection Bias Domain: ITT Analysis? Performance Bias Domain: Care P…

65. Comparative Effectiveness of Pharmacologic Therapies for the Management of Crohn’s Disease | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/crohns-disease/research-protocol
    December 01, 2019 - To the extent that we can, we will collect and analyze data by various subgroups, including disease location … For our population of interest, we have added a statement that we will analyze adults and children separately … We will analyze the data assuming both homogeneous variance and heterogeneous variance.

66. Management of Insomnia Disorder | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/insomnia/research
    December 01, 2019 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

67. App-G-Surv-Report-3-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-g-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
    September 20, 2022 - RCTs Table G-1. Quality assessments of included randomized controlled trials Author, Year Randomization Adequate Allocation Concealment Adequate Patients and Personnel Masked Outcome Assessors Masked Groups Similar at Baseline Intent-to-Treat Analysis (at Least 95% Analyzed) Attrition <20%; Difference Between Groups …

68. Medical Therapies for Locally Advanced Gastric Adenocarcinoma (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/gastric-cancers-protocol-amended.pdf
    February 07, 2025 - To reduce clinical heterogeneity, we will analyze studies of patients with resectable tumors or who … For other subgroups which may be effect modifiers such as biomarkers and functional status, we will analyze … We will analyze RCTs and NRSIs separately unless there is reason to believe the studies are sufficiently

69. Medical Therapies for Locally Advanced Gastric Adenocarcinoma | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/gastric-cancers/protocol
    February 01, 2025 - To reduce clinical heterogeneity, we will analyze studies of patients with resectable tumors or who are … For other subgroups which may be effect modifiers such as biomarkers and functional status, we will analyze … We will analyze RCTs and NRSIs separately unless there is reason to believe the studies are sufficiently

70. Evidence Report on the (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/crohns-disease_research-protocol.pdf
    September 01, 2010 - • To the extent that we can, we will collect and analyze data by various subgroups, including disease … considering for this review. 2) For our population of interest, we have added a statement that we will analyze … We will analyze the data assuming both homogeneous variance and heterogeneous variance.

71. Layout 1 (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cancer-anemia_executive.pdf
    May 01, 2006 - Layout 1 Background Anemia (deficiency of red blood cells) occurs in 13-78 percent of patients undergoing treatment for solid tumors and 30-40 percent of patients treated for lymphoma. Tumor type, treatment regimen, and history of prior cancer therapy influence the risk and severity of anemia. For example, among pa…

72. Cer-265-Radiation-Bone-Disease-Addendum-App (xls file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-265-radiation-bone-disease-addendum-app.xlsx
    October 12, 2023 - Title Addendum Appendix - Evidence Table Table1. Evidence Table Addendum Table 1. Evidence table for a randomized controlled trial evaluating external beam radiation therapy for the palliative treatment of metastatic bone disease identified after submission of final report and summarized in …

73. Using Collaborative Platforms for Communities of Practice (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/grama.pdf
    January 06, 2017 - Using Collaborative Platforms for Communities of Practice INNOVATIONS CONFERENCE -- NATIONAL CANCER INSTITUTE SPEAKER: LAKSHMI GRAMA, SENIOR DIGITAL CONTENT STRATEGIST, NATIONAL CANCER INSTITUTE (NCI) GRAMA: I’m Lakshmi Grama from the Office of Communications and Education at the National …

74. Disposition of Comments Report for Comparative Effectiveness Review #68 (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/nppv-respiratory-failure_disposition-comments.pdf
    July 01, 2012 - The analyses have been revised to analyze these groups separately. … analysis where they combined the data across all patient populations The analyses have been revised to analyze … We have revised KQ3 to analyze 3 separated groups: NPPV used to wean from invasive ventilation, NPPV … We have revised KQ3 to analyze 3 separated groups: NPPV used to wean from invasive ventilation, NPPV

75. Diagnosis and Treatment of Clinical Alzheimer's-Type Dementia | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/alzheimers-type-dementia/research
    October 01, 2022 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

76. Arcia-notes-Teresa (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/arcia-presentation.pdf
    November 11, 2015 -  be capturing al of the user actions in the system logs that we can later download the log files to analyze … Also, if we could analyze the log files as people are using the tool, could  use their usage patterns

77. Omega-3 Fatty Acids and Cardiovascular Disease: Current State of the Evidence (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/fatty-acids-cardiovascular-disease_clinician.pdf
    July 01, 2017 - Omega-3 Fatty Acids and Cardiovascular Disease: Current State of the Evidence Omega-3 Fatty Acids and Cardiovascular Disease: Current State of the Evidence Focus of This Summary This is a summary of a systematic review that evaluated the recent evidence regarding the effects of omega-3 fatty acids (FAs), primaril…

78. A Prospective Comparison of Evidence Synthesis Search Strategies Developed With and Without Text-Mining Tools | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/research-strategies-text-mining-tools/methods-report
    March 01, 2021 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

79. Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/antiplatelet-treatment/research
    December 01, 2019 - Skip to main content An official website of the Department of Health & Human Services Careers Contact Us Español FAQs Effective Health Care Program Powered by the Evidence-based Practice Centers …

80. Imaging Tests for the Staging of Colorectal Cancer | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/colorectal-cancer-staging/research-protocol
    December 01, 2020 - colon cancer for inclusion in the report, when possible (as permitted by the reported data), we will analyze … of the rectal tumor—low, middle, or high—may also affect staging accuracy, so when possible we will analyze … and distal colon cancer may also be distinctly different conditions; so if possible, we will try to analyze … For studies of test performance, we will meta-analyze the data reported by the studies using a bivariate … midas” command. 31 In cases in which a bivariate binomial regression model cannot be fit, we will meta-analyze